Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients

Pediatric Transplantation

Volumn 5, Issue 5, 2001, Pages 359-364

  Cacciarelli, Thomas V ^a,b   Reyes, Jorge ^a   Jaffe, Ronald ^a   Mazariegos, George V ^a   Jain, Ashok ^a   Fung, John J ^a   Green, Michael ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Liver transplantation; Post transplant lymphoproliferative disease; Tacrolimus

Indexed keywords

ACICLOVIR; METHYLPREDNISOLONE; OKT 3; ORTHOCLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CHILD; COHORT ANALYSIS; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MORTALITY; PEDIATRIC SURGERY; POSTOPERATIVE COMPLICATION; RISK ASSESSMENT; STATISTICAL ANALYSIS;

ADOLESCENT; CHILD; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; TACROLIMUS;

EID: 0034845033     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2001.00021.x     Document Type: Article

References (21)

1. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation
2. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK506
3. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporine A
4. Tacrolimus: A review of its pharmacology and therapeutic potential in hepatic and renal transplantation
5. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine and lymphoproliferative disease: A growing concern
6. An increased incidence of Epstein-Barr Virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation
7. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression
8. Early signs and risk factors for the increased incidence of EpsteinBarr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus
9. Assay of FK506 in plasma
10. The pathology of posttransplant lymphoproliferative disorder occurring in the setting of cyclosporine-A prednisone immunosuppression
11. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplant lymphoproliferative disease
12. Epstein-Barr virus and its replication
13. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency
14. Epstein-Barr virus
15. Immune regulation in Epstein-Barr virus-associated diseases
16. Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens
17. Epstein-Barr virus infections: Biology, pathogenesis, and management
18. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state
19. The frequency of EpsteinBarr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestation in children
20. A whole blood FK506 assay for IMx analyzer
21. Oral tacro-limus (FK506) induction therapy in pediatric orthotopic liver transplantation